ClinicalTrials.gg
CompletedNCT04607733Updated Feb 20, 2024Results posted

A Study of Mirikizumab in Healthy Participants

A Phase 1 interventional study of Mirikizumab Prefilled Syringe and Mirikizumab Autoinjector in Healthy, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to compare the amount of mirikizumab that gets into the blood stream and how long it takes the body to get rid of it, when given as a solution formulation via manual prefilled syringe or autoinjector. The information about any adverse effects experienced will be collected and the tolerability of mirikizumab will also be evaluated.

Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be about 17 weeks, including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or females, as determined through medical history and physical examination

Exclusion criteria

Exclusion Criteria:

  • Must not have an average weekly alcohol intake that exceeds 21 units/week (males) and 14 units/week (females)
  • Must not show evidence of active or latent tuberculosis (TB)
  • Must not have received (s) (including attenuated live vaccines and those administered intranasally) within 8 weeks of screening, or intend to during the study
  • Must not have been treated with within 1 month of screening, or intend to during the study
  • Must not be
  • Must not have received treatment with biologic agents (e.g. monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to Day 1
  • Must not have multiple or severe drug allergies, or intolerance to topical corticosteroids, or severe post treatment reactions
  • Must not have had lymphoma, leukemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years
  • Must not have had breast cancer within the past 10 years
  • Must not have significant allergies to humanized monoclonal antibodies
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Mirikizumab - Prefilled Syringe

    2× 1mL (total 200 milligrams (mg) mirikizumab) administered by subcutaneous injection (SC) via a prefilled syringe (PFS)

    Drug: Mirikizumab Prefilled Syringe

  • Experimental
    Mirikizumab - Autoinjector

    2× 1mL (total 200 milligrams (mg) mirikizumab) administered by subcutaneous injection (SC) via an autoinjector (AI)

    Drug: Mirikizumab Autoinjector

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab

    PK: Cmax of Mirikizumab

    Time frame: Predose up to 85 days postdose

  2. PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab

    PK: AUC\[0-∞\] of Mirikizumab

    Time frame: Predose up to 85 days postdose

  3. PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab

    PK: AUC\[0-tlast\] of Mirikizumab

    Time frame: Predose up to 85 days postdose

07

Results

Posted Feb 20, 2024

Participant flow

Participant flow — Overall Study
MilestoneAI (Test) AbdomenAI (Test) ArmAI (Test) ThighPFS (Reference) AbdomenPFS (Reference) ArmPFS (Reference) Thigh
Started403941404139
Received at least one dose of drug403941404139
Completed393941393939
Not completed100120
Withdrew: Lost to follow-up100110
Withdrew: Withdrawal by subject000010

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab

PK: Cmax of Mirikizumab

Time frame:
Predose up to 85 days postdose
Reported as:
Geometric least squares mean · micrograms/milliliter (µg/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab
micrograms/milliliter (µg/mL)PFS (Reference)AI (Test)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab14.3 ± 4415.2 ± 40
PrimaryPK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab

PK: AUC\[0-∞\] of Mirikizumab

Time frame:
Predose up to 85 days postdose
Reported as:
Geometric mean · micrograms*day/milliliter (µg*day/mL)
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab
micrograms*day/milliliter (µg*day/mL)PFS (Reference)AI (Test)
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab246 ± 44262 ± 39
PrimaryPK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab

PK: AUC\[0-tlast\] of Mirikizumab

Time frame:
Predose up to 85 days postdose
Reported as:
Geometric mean · micrograms*day/milliliter (µg*day/mL)
PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab
micrograms*day/milliliter (µg*day/mL)PFS (Reference)AI (Test)
PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab244 ± 44257 ± 39

Adverse events

Collected over Baseline Up To 85 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AI (Test) Abdomen0/40 (0%)0/40 (0%)7/40 (17.5%)
AI (Test) Arm0/39 (0%)0/39 (0%)6/39 (15.4%)
AI (Test) Thigh0/41 (0%)0/41 (0%)8/41 (19.5%)
PFS (Reference) Abdomen0/40 (0%)0/40 (0%)6/40 (15%)
PFS (Reference) Arm0/41 (0%)0/41 (0%)5/41 (12.2%)
PFS (Reference) Thigh0/39 (0%)0/39 (0%)6/39 (15.4%)
Most frequent other events
Most frequent other events
EventAI (Test) AbdomenAI (Test) ArmAI (Test) ThighPFS (Reference) AbdomenPFS (Reference) ArmPFS (Reference) Thigh
HeadacheNervous system disorders5/404/393/414/402/413/39
Injection site reactionGeneral disorders3/403/394/412/404/413/39
Covid-19Infections and infestations0/401/392/411/400/412/39

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)AI (Test)PFS (Reference)Total
Mean43.3 ± 12.040.1 ± 12.441.7 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)AI (Test)PFS (Reference)Total
Female6871139
Male5249101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AI (Test)PFS (Reference)Total
Hispanic or Latino212041
Not Hispanic or Latino99100199
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AI (Test)PFS (Reference)Total
American Indian or Alaska Native123
Asian224
Native Hawaiian or Other Pacific Islander011
Black or African American193049
White9783180
More than one race112
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(Participants)AI (Test)PFS (Reference)Total
United States120120240
08

Study locations

4 sites
  • Covance Clinical Research Inc
    Daytona Beach, Florida 32117, United States
  • QPS
    Springfield, Missouri 65802, United States
  • Covance Dallas
    Dallas, Texas 75247, United States
  • Covance Clinical Research Inc
    Madison, Wisconsin 53704, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in May 2021, 6 months.

Results were first posted in Feb 2024, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2020
First posted
Oct 29, 2020
StartActual
Nov 2, 2020
Primary completionActual
May 17, 2021
CompletionActual
May 17, 2021
Results first posted
Feb 20, 2024
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04607733
Responsible party
Sponsor
First posted
Oct 29, 2020
Start date
Nov 2, 2020
Primary completion
May 17, 2021
Completion
May 17, 2021
Results posted
Feb 20, 2024
Last update
Feb 20, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion